Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence

Detalles Bibliográficos
Autores principales: De, Dipankar, Pandhi, Deepika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
IADVL COVID-19 Symposium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413441/
https://www.ncbi.nlm.nih.gov/pubmed/32832437
http://dx.doi.org/10.4103/idoj.IDOJ_414_20
_version_ 1783568797131603968
author De, Dipankar
Pandhi, Deepika
author_facet De, Dipankar
Pandhi, Deepika
author_sort De, Dipankar
collection PubMed
description
format Online
Article
Text
id pubmed-7413441
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-74134412020-08-20 Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence De, Dipankar Pandhi, Deepika Indian Dermatol Online J IADVL COVID-19 Symposium Wolters Kluwer - Medknow 2020-07-13 /pmc/articles/PMC7413441/ /pubmed/32832437 http://dx.doi.org/10.4103/idoj.IDOJ_414_20 Text en Copyright: © 2020 Indian Dermatology Online Journal http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle IADVL COVID-19 Symposium
De, Dipankar
Pandhi, Deepika
Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence
title Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence
title_full Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence
title_fullStr Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence
title_full_unstemmed Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence
title_short Use of Immunosuppressants/Immunomodulators in Autoimmune/Inflammatory Dermatologic Diseases during COVID-19 Pandemic—General Recommendation Based on Available Evidence
title_sort use of immunosuppressants/immunomodulators in autoimmune/inflammatory dermatologic diseases during covid-19 pandemic—general recommendation based on available evidence
topic IADVL COVID-19 Symposium
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413441/
https://www.ncbi.nlm.nih.gov/pubmed/32832437
http://dx.doi.org/10.4103/idoj.IDOJ_414_20
work_keys_str_mv AT dedipankar useofimmunosuppressantsimmunomodulatorsinautoimmuneinflammatorydermatologicdiseasesduringcovid19pandemicgeneralrecommendationbasedonavailableevidence
AT pandhideepika useofimmunosuppressantsimmunomodulatorsinautoimmuneinflammatorydermatologicdiseasesduringcovid19pandemicgeneralrecommendationbasedonavailableevidence

Ejemplares similares